PineTree Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
767C Concord Ave, Cambridge, Massachuset...Phone Number
(857) 654-4850Website
www.pinetreetx.comRevenue
$9.1 MillionIndustry
About PineTree Therapeutics
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms, and has entered strategic partnerships, including a licensing agreement with AstraZeneca.Explore more
PineTree Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to PineTree Therapeutics
Compare insights from companies similar to PineTree Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PineTree Therapeutics Tech Stack
A closer look at the technologies used by PineTree Therapeutics
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding PineTree Therapeutics
Sign Up For FreeTo access detailed company insights
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor platform enables selective degradation of membrane-bound and extra... Read More
